BRIEF published on 12/09/2025 at 14:55, 8 days 5 hours ago Teva Pharmaceuticals submits an application for authorization for Olanzapine LAI FDA Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI
BRIEF published on 12/09/2025 at 14:55, 8 days 5 hours ago Medincell and Teva Submit FDA Application for New Injectable Treatment Schizophrenia Treatment Medincell FDA Submission Teva Pharmaceuticals Olanzapine LAI
PRESS RELEASE published on 12/09/2025 at 14:50, 8 days 5 hours ago Inside Information / Other news releases Teva Pharmaceuticals submits NDA to FDA for Olanzapine Extended-Release Injectable Suspension (TEV-'749 / mdc-TJK) for Once-Monthly Schizophrenia Treatment. Medincell focuses on long-acting injectable treatments across therapeutic areas Schizophrenia Medincell Olanzapine NDA Teva Pharmaceuticals
BRIEF published on 11/11/2025 at 08:05, 1 month 6 days ago Medincell Expands Dr Grace Kim's Role to Boost US Capital Growth Biotechnology Medincell Pharmaceutical Strategy Dr Grace Kim US Capital Growth
PRESS RELEASE published on 11/11/2025 at 08:00, 1 month 6 days ago Inside Information / Other news releases Medincell appoints Dr. Grace Kim as Chief Strategy Officer, U.S. Finance to lead U.S. capital growth strategy. Medincell pioneers long-acting injectable therapies Medincell Dr. Grace Kim Long-acting Injectable Therapies U.S. Capital Growth Clinical-stage Pharmaceutical Company
BRIEF published on 11/05/2025 at 13:51, 1 month 12 days ago Continued growth for Medincell and new prospects with Olanzapine LAI Schizophrenia Medincell Teva Pharmaceuticals Olanzapine LAI UZEDY
PRESS RELEASE published on 11/05/2025 at 13:46, 1 month 12 days ago Inside Information / Other news releases Medincell's partner Teva plans US NDA submission for Olanzapine LAI in Q4 2025, while UZEDY® achieves continued growth in sales in Q3 2025 Medincell Teva Pharmaceuticals Olanzapine LAI US NDA Submission UZEDY Sales Growth
BRIEF published on 10/10/2025 at 22:16, 2 months 6 days ago FDA Approves UZEDY for Bipolar I Disorder in Adults FDA Approval Mental Health Treatment UZEDY Bipolar I Disorder Risperidone
PRESS RELEASE published on 10/10/2025 at 22:11, 2 months 6 days ago Inside Information / Other news releases FDA approves UZEDY as extended-release injectable suspension for bipolar I disorder treatment in adults. Teva and Medincell collaborate on this significant advancement in neuroscience FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 09/17/2025 at 14:05, 3 months ago Medincell and Teva Present Phase 3 Olanzapine LAI Data Phase 3 Trial Schizophrenia Treatment Medincell Teva Olanzapine LAI
Published on 12/17/2025 at 15:00, 5 hours 32 minutes ago BlackBerry Unveils Ground-Up Modernization of BlackBerry AtHoc Mobile Experience to Enable More Intelligent Operations
Published on 12/17/2025 at 14:00, 6 hours 32 minutes ago UniDoc Completes H3 Health Cube Installation in Italy
Published on 12/17/2025 at 13:35, 6 hours 57 minutes ago Silver X Mining Announces Grant of Incentive Stock Options and Restricted Share Units
Published on 12/17/2025 at 13:15, 7 hours 17 minutes ago Aclara Wins UN Global Compact Award for Its Contribution to Local Employment and Suppliers
Published on 12/17/2025 at 13:00, 7 hours 32 minutes ago Gold Terra Provides a Summary of 2025 Achievements and 2026 Plan
Published on 12/17/2025 at 20:12, 20 minutes ago EQS-Adhoc: Rheinmetall AG: Executive Board decides to sell activities of the civil division Power Systems – Target is sale in the first quarter of 2026; update of outlook for continuing operation
Published on 12/17/2025 at 19:39, 52 minutes ago Avolta awarded Shanghai Pudong International Airport concession, marking a first-in-a-generation duty-free win for an international operator in mainland China
Published on 12/17/2025 at 19:10, 1 hour 22 minutes ago Holand Automotive Group Announces the sale of Ferrari Rancho Mirage to Lapis Automotive Group
Published on 12/17/2025 at 18:39, 1 hour 53 minutes ago EQS-Adhoc: centrotherm international AG: Centrotherm AcquiCo AG submits request for the squeeze-out of minority shareholders of centrotherm international AG
Published on 12/17/2025 at 18:00, 2 hours 32 minutes ago Outstanding Shares and Voting Rights Statement at 30 November 2025
Published on 12/17/2025 at 17:51, 2 hours 41 minutes ago Mr.Bricolage: Completion of the simplification of the Mr.Bricolage Group’s shareholding structure
Published on 12/17/2025 at 17:50, 2 hours 42 minutes ago The Council of Paris approves the selection of Dalkia/Eiffage/RATP Solutions Ville consortium for Paris district heating network concession renewal.
Published on 12/17/2025 at 17:45, 2 hours 47 minutes ago Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2025
